Buy Spevigo (spesolimab-sbzo) Online For Sale
DISEASE INDICATIONS: Psoriasis
MANUFACTURER: Boehringer Ingelheim
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Spevigo (spesolimab-sbzo) is a humanized monoclonal antibody that targets the protein interleukin-36 (IL-36) to treat moderate-to-severe plaque psoriasis in adults. The medication is administered via intravenous infusion and inhibits the formation of proinflammatory cytokines that contribute to the development of psoriasis.
Spevigo (spesolimab-sbzo) is a prescription medication used to treat adults with moderate-to-severe plaque psoriasis. It is a humanized monoclonal antibody that selectively targets the protein interleukin-36 (IL-36), which plays a critical role in the pathogenesis of psoriasis. By binding to IL-36, spesolimab-sbzo inhibits the formation of proinflammatory cytokines, which are believed to contribute to the development of this chronic skin disorder.
Psoriasis is an autoimmune condition characterized by the development of red, scaly plaques on the skin. It is caused by the immune system attacking healthy skin cells, leading to an overproduction of new cells that accumulate on the surface of the skin. The resulting red, scaly patches can be itchy, painful, and unsightly, and can have a significant impact on a person’s quality of life. Psoriasis can also be associated with comorbid conditions, such as psoriatic arthritis, cardiovascular disease, and depression.
Spevigo is administered as an intravenous infusion in a healthcare setting. The recommended dosage is 30 mg/kg, given once every four weeks until week 20, followed by 30 mg/kg every 12 weeks thereafter. Patients should be monitored for hypersensitivity reactions during and after the infusion, as well as for signs of infection.
In clinical trials, spevigo has been shown to be an effective treatment for moderate-to-severe plaque psoriasis. In two phase 3 clinical trials, more than half of patients treated with spesolimab-sbzo achieved at least a 90% improvement in their Psoriasis Area and Severity Index (PASI 90) score, compared to about 2-5% of patients in the placebo group. Additionally, the medication showed sustained efficacy over time, with more than 80% of patients who initially responded to the medication maintaining their response through week 52.
Despite its efficacy, spevigo is associated with some potential side effects. The most common adverse reactions include upper respiratory tract infections, injection site reactions, and diarrhea. Patients should be monitored for serious infections, as treatment with spevigo may increase the risk of developing bacterial, fungal, and viral infections. There have also been reports of other serious side effects, such as anaphylaxis, and patients receiving the medication should be closely monitored for these and other potential reactions.
In summary, Spevigo (spesolimab-sbzo) is a humanized monoclonal antibody that selectively targets the protein interleukin-36 (IL-36) for the treatment of moderate-to-severe plaque psoriasis in adults. It inhibits the formation of proinflammatory cytokines, which contribute to the development of this chronic skin disorder. The medication is administered as an intravenous infusion, and patients should be monitored for potential side effects, including upper respiratory tract infections, injection site reactions, and diarrhea. Despite its efficacy, the medication may increase the risk of developing serious infections and other potential reactions that must be closely monitored.
450 mg/7.5 mL (60 mg/mL) x 1 single-dose vial